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Summary Confocal microscopy was used to visualize the intracellular uptake of the fluorescent methotrexate analogue, fluorescein-MTX (F-
MTX), in human leukaemic cell lines and leukaemic blasts. Cytosolic labelling of wild-type K562 human erythroleukaemia cells was detected
during 3-60 min incubations with F-MTX (1 giM) and was completely inhibited by co-exposure to either methotrexate or the thymidylate
synthase inhibitor, ZD1694. There was no significant intracellular F-MTX accumulation over this period in a K562 subline (K500E) with a
documented defect (approximately 10% of wild type) in membrane transport by the reduced folate carrier (RFC). F-MTX uptake was re-
established in K500E cells transfected with a cDNA to human RFC, establishing a role for RFC in the cellular uptake of this compound. High
levels of intracellular labelling were detected in all cell lines after prolonged (24 h) F-MTX incubations, however F-MTX accumulation at this
time was not inhibited by ZD1694. F-MTX uptake by RFC was also detected in leukaemic blasts from children with acute lymphoblastic
leukaemia and could be blocked with ZD1694. In leukaemic blasts with a documented defect in MTX uptake, F-MTX accumulation was
abolished in almost all the cells. These results display the power of confocal microscopy for directly visualizing RFC-mediated anti-folate
uptake. Over short intervals, F-MTX uptake is mediated by RFC, however, RFC-independent processes predominate during long drug
exposures. Direct assay by confocal microscopy may be better suited than other indirect methods (i.e. flowcytometry) fordetecting low levels
of RFC transport in leukaemic blasts from patients undergoing chemotherapy with methotrexate.
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The folate analogue, methotrexate (MTX) is an important
component in the chemotherapy of childhood acute lymphocytic
leukaemia (ALL). Although long-term disease-free survival for
children with ALL has continued to increase and now approaches
70% (Pizzo and Poplack, 1993), further improvements in ALL
treatment will have better results ifpatients who may benefit from
more intensive therapies can be identified.
Critical determinants of MTX sensitivity and resistance have
been previously described in cultured cells (Jolivet et al, 1983;
Goldman and Matherly, 1985). MTX is transported into cells by
the reduced folate carrier (RFC) where it binds to dihydrofolate
reductase (DHFR) and is metabolized to MTX polyglutamates by
folylpolyglutamate synthetase (FPGS). Lymphoblasts from chil-
dren with ALL also synthesize long-chain MTX polyglutamates
(Whitehead et al, 1990), and correlations have been established
between accumulation of these metabolites and characteristic
patient prognostic features (i.e. lineage, hyperdiploidy, etc.)
or MTX dose (Whitehead et al, 1992; Barredo et al, 1994; Synold
et al, 1994).
In recent years, fluorescent analogues of MTX have fostered
studies of MTX resistance in cultured cells and leukaemic blasts
by flow cytometry (Kaufman et al, 1978; Rosowsky et al, 1982;
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Assaraf and Schimke, 1987; Trippett et al, 1992; Matherly et al,
1995). The most extensively studied ofthese compounds, fluores-
cein MTX (F-MTX), has been reported to penetrate cells slowly
over several hours and to accumulate to high levels in both MTX-
sensitive and transport-impaired cells (Assaraf and Schimke,
1987), presumably by a non-RFC uptake process. As F-MTX
binds avidly to DHFR, it has frequently been used to detect
elevated levels of this enzyme target in MTX-resistant cells by
flow cytometry (Kaufman et al, 1978). Whereas capacities for
MTX membrane transport can also be assayed with F-MTX and
flow cytometry, by following the loss ofcellular fluorescence due
to the competitive displacement of DHFR-bound F-MTX with
exogenous MTX (Assaraf and Schimke, 1987), the sensitivity of
this indirect assay of RFC function is limited by the range of
displacing MTX concentrations used.
On this basis, we sought to develop a more direct and sensitive
approach for assaying RFC function in intact cells that might be
amenable to the study of clinical specimens. In this report, we
describe the use ofconfocal microscopy to visualize directly aRFC-
mediated uptake ofF-MTX that is potently inhibited by RFC-trans-
port substrates and is completely abolished in cultured cells with
impaired MTX transport. Initial experiments are also described that
extend the use of this approach to the detection of RFC transport
competent and impaired leukaemic blasts from children with ALL.
Our data show a high level of sensitivity for confocal analysis,
reflecting its enhanced image resolution over standard fluorescence
microscopy and an ability to establish the intracellular (as opposed










Figure 1 Confocal detection of F-MTX uptake by wild-type, transport-impaired and RFC-transfected K562 cells. A-D are cross-sections ofwild-type K562 cells after 15-min incubations with 1 gM F-MTX alone (A), 15 min with added ZD1694 (B), 24 h alone (C) or 24 h with added ZD1694 (D). E-H are cross-sections of K500E cells after 15-min incubations with F-MTX alone (E), 15 min with added ZD1694 (F); 24 h alone (G) or 24 h with added ZD1694 (H). l-L are cross-
sections of K43-6 cells after 15-min incubations with F-MTX alone (I), 15 min with added ZD1694 (J), 24 h alone (K) or 24 h with added ZD1694 (L). The final ZD1694 concentration was 100gM. The darkened area totally devoid offluorescence staining in most sections is the cell nucleus. All images were printed with a Focus camera system using false colours to simulate fluorescence intensity, with lowest to highest intensities represented sequentially by the colours blue, green, yellow, red and white. The scale bar represents 5 gm
MATERIALS AND METHODS
Chemicals
F-MTX was purchased from Molecular Probes (Eugene, OR, USA)
and MTX was obtained from Sigma Chemical (St. Louis, MO,
USA). ZD1694 (N-(5-(N-(3,4-dihydro-2-methyl-4-oxyquinazolin-
6-ylmethyl)-N-methylamino)-2-thenoyl)-L-glutamic acid) was
provided by DrAnnJackman (Institute ofCancerResearch, Surrey,
UK). Tissue culture reagents and supplies were purchased from
assorted vendors except iron-supplemented calf serum, which was
obtained from Hyclone Laboratories (Logan, UT, USA).
Cell culture
The wild-type K-562 human erythroleukaemia cell line was
obtained from the American Type Culture Collection (Rockville,
MD, USA). The transport-impaired K500E subline was selected
from wild-type K562 cells by cloning in soft agar in the presence
of500 nm MTX (Matherly et al, 1992). K500E cells were approx-
imately 90% transport impaired by direct assay with [3H]MTX
(Wong et al, 1997). The K500E cell line was transfected with the
human RFC cDNA-pcDNA3 construct (Wong et al, 1995) using
lipofectin (Buonocore and Rose, 1991). A G418-resistant clone
(designated K43-6) was selected by cloning in soft agar and char-
acterized for increased MTX sensitivity and completely restored
RFC transport. The characteristics ofthe K43-6 transfectants were
recently described (Wong etal, 1997). All lines were maintained in
RPMI-1640 medium, containing 10% heat-inactivated iron-
supplemented calf serum, 2 MM L-glutamine, 100 U ml-' peni-
cillin, and 100 ,ug ml-' streptomycin in ahumidifiedatmosphere at
37°C in the presence of 5% carbon dioxide/95% air. K500E cells
were continuously maintained in the presence of 500 nrm MTX;
before confocal experiments, cells were cultured for 3-5
generations without MTX. Transfected cells were maintained in
1 mgml' G418. Cell lines were subcultured every 96h. Cell
numbers weredeterminedby directcounting with ahaemacytometer.
Patient specimens
Three archival cryopreserved ALL specimens from our previous
report (Matherly et al, 1995), with documented DHFR and MTX
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Figure 2 Confocal detection of F-MTX uptake by leukaemic cells from patients with ALL. A to C are cross-sections of leukaemic blasts (sample nos 2, 26 and
12 respectively, from Matherly et al, 1995) after 15-min incubations with 1 gM F-MTX. The darkened area totally devoid of fluorescence staining is the cell
nucleus (labelled 'n' in B). All images were printed as described in Figure 1. The scale bar represents 5 gm
transport capacities, were studied. Blasts were previously purified
by standard Ficoll-Hypaque density centrifugation and had high
blast counts (87-95%) and good viabilities (> 90%) at the time of
experiment. Cells were thawed and suspended for 20 h in complete
RPMI-1640 medium containing 10% serum before incubation
with F-MTX, as described below. Specimen no. 2 was from a
patient with B-precursor ALL at diagnosis and specimen no. 26
was from a T-ALL patient at relapse; both samples exhibited
normal DHFR and MTX transport by a flow cytometry assay
(Matherly et al, 1995). Diagnostic B-precursor specimen no. 12
exhibited heterogeneously increased DHFR (in 14% of the blasts)
and impaired MTX transport (in 17% of the blasts). Our previous
study (Matherly et al, 1995) showed that MTX transport was func-
tionally intact in previously cryopreserved ALL specimens.
Confocal microscopy experiments
Log-phase K562, K500E and K43-6 cells were incubated at
370C with 1 ,UM F-MTX in culture medium supplemented with
16 gM thymidine and 100 jM hypoxanthine for up to 24 h. Control
incubations were performed in the presence ofeither 500 gM MTX
or 100 gM ZD1694. After incubations of3, 5, 15, 60 min and 6 and
24 h, the cells were fixed with a freshly prepared solution of 4%
paraformaldehyde in phosphate-buffered saline (PBS) for 20 min
at 4°C and rinsed three times with ice-cold PBS. The cells were
mounted on slides with Aquapolymount for confocal microscopic
analysis. For the experiments with the patient blasts, cells were
incubated in Hanks' balanced salts with 1 ,UM F-MTX with and
without 100 gM ZD1694 at 370C for 15, 30 and 60 min. Cell densi-
ties were 1.5-3 million cells per 600 ,uL. The cells were fixed,
washed and mounted as described above.
Confocal microscopic images were acquired on a Leica confocal
scanning laser microscope. Scanning was made at 4.0 electronic
zoom so that at a magnification of x 40 (using a fluotar oil immer-
sion objective) the final (x,y) resolution was 1 pixel per 0.245 jim.
Images of single cells were acquired by putting one optical section
through the cell centre with 32 scans per frame. For all acquisitions,
the gain and black levels were setmanually to optimize the dynamic
range of the image while ensuring that no region was completely
suppressed (intensity =0) or completely saturated (intensity = 255).
All images were stored on an optical disk and printed using a Focus
camera system that used false colours to simulate fluorescence
intensity. Representative pictures of the fluorescent patterns
observed in the different experiments performed are shown in
Figures 1 and 2. Each experimental condition illustrated for the cell
line experiments (Figure 1) was carried out on three different occa-
sions. The patient experiments (Figure 2) were only perfomed twice
because of the limited availability of samples. A total of 100 cells
per slide was analysed and scanned. The selected field for analysis
was chosen randomly on each slide. There was a very good homo-
geneity in the fluorescent patterns observed among different cells
on the same slides. In the experimental conditions in which cells
were labelled, about 70-75% of the cells were fluorescent with
consistent intensity and labelling pattern.
RESULTS
Confocal microscopy images for wild-type K562 cells (A-D),
their transport deficient subline (K500E; E-H) and KSOOE cells
transfected with the human RFC cDNA (designated K43-6; I-L)
are shown in Figure 1, following incubations with 1 ,UM F-MTX. In
the wild-type K562 line, intracellular fluorescence labelling was
maximal as early as 5 min after exposure to F-MTX (Figure IA
shows the labelling at 1S min) and was highly homogeneous; most
ofthe fluorescence was localized in the cytosol. In the presence of
100 gM ZD1694 (Figure IB) or 500 gM MTX (not shown), F-
MTX fluorescence uptake was virtually completely abolished
during incubations up to 60 min, establishing a role for the RFC in
F-MTX uptake over this interval. Although there was a complete
absence ofF-MTX uptake over 60 min in K500E cells (Figures IE
and F), fluorescence uptake was re-established in the K43-6 trans-
fectants (Figure 11). The fluorescence uptake in K43-6 cells was
more heterogeneous (not shown) and was frequently more intense
than for the wild type cells. Further, F-MTX uptake could be
blocked with ZD1694 (Figure 1J).
Although the early time course labelling data strongly suggested
a RFC-mediated uptake component for F-MTX, cellular fluores-
cence accumulations were essentially identical in all cell lines
following sustained F-MTX exposures (24h; Figures IC, G and K).
Furthermore, co-incubation with ZD1694 did not affect F-MTX
labelling at 24 h (Figures ID, H and L). In contrast, MTX (500gM)
partially decreased fluorescence in wild-type cells at this time (not
shown), presumably because ofcompetition for DHFR binding.
Confocal images of F-MTX uptake by the leukaemic blast cells
from children with ALL are illustrated in Figure 2. Blast cells were
significantly smaller than the cultured cell lines and typically exhib-
ited large nuclei and greatly reduced cytosol. Two ofthe blast spec-
imens (no. 2 and no. 26) previously reported to have intact RFC
transport (Matherly et al, 1995), accumulated high levels ofF-MTX
over 15 min that appeared as intense, perinuclear punctate fluores-
cence (Figure 2A and B respectively). As for the cultured cells,
cellular fluorescence was maximal within 5 min and was essentially
unchanged for up to 60 min and was nearly completely abolished in
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the presence of 100 gM ZD1694 (not shown). For a B-precursor
specimen (no. 12) with a documented impairment in MTX uptake
(Matherly et al, 1995), there was no detectable F-MTX accumula-
tion in over 90% ofthe blasts examined (Figure 2C).
DISCUSSION
The enhanced image resolution of confocal microscopic analysis
and the possibility of doing a series of optical sections of the
human leukaemic cells studied, allowed for the intracellular local-
ization ofthe F-MTX probe. (Although F-MTX is primarily local-
ized to the cytosol rather than sequestered in organelles such as the
mitochondria and lysosomes, its distribution to these compart-
ments cannot be discounted. Further, it is not inconceivable that
because of its lack of polyglutamylation, F-MTX may exhibit a
different intracellular distribution from methotrexate.) It also
allowed us to observe a RFC-specific component of F-MTX
uptake that could not be identified by conventional fluorescence
microscopy or flow cytometry. Fluorescence was barely visible by
conventional microscopy in the leukaemic cell lines and we could
not reproducibly document F-MTX uptake by flow cytometry
after short F-MTX incubations. During short time exposures to F-
MTX (< 15 min), no appreciable increase in relative fluorescence
was detected over high background autofluorescence. Only after
prolonged drug exposures (> 6 h) was there a sufficient fluorescent
signal for dependable flow cytometry detection (data not shown).
The recent cloning ofRFC cDNAs (Dixon et al, 1994; Williams et
al, 1994; Moscow et al, 1995; Williams and Flintoff, 1995; Wong
et al, 1995) and the availability ofa RFC-deficient human cell line
stably transfected with a RFC cDNA (Wong et al, 1997) allowed
us to directly establish that F-MTX uptake during short incuba-
tions was mediated by the RFC. Although F-MTX labelling was
highly homogeneous in wild type K562 and KSOOE sublines, in
the RFC transfectants fluorescence was more heterogeneous and,
frequently, more intense than wild-type cells. The latter finding is
consistent with greater RFC expression (15-fold) and transport
(twofold) in transfected over wild-type cells (Wong et al, 1997).
Morever, both the K500E and K43-6 lines exhibit a 7.7-fold
increased DHFR content over wild-type cells (Wong et al, 1997).
The RFC-specific uptake of F-MTX was further confirmed by
co-incubation studies with MTX and ZD1694. Both these anti-
folates preferentially use the RFC for transmembrane transport
(Jackman et al, 1991; Westerhof et al, 1995) and almost
completely prevented F-MTX uptake in RFC-competent cells
during short incubations. The decrease in cellular labelling by the
thymidylate synthase inhibitor ZD1694 confirmed that this obser-
vation could not be simply explained by intracellular probe
displacement from DHFR. F-MTX did accumulate in both RFC-
competent and deficient cells after longer incubations, presumably
via nonspecific diffusion (Henderson et al, 1980; Assaraf et al,
1989). [Although the nature of this process is unestablished, it is
clear that it does not involve RFC. Based on folic acid growth
requirements and our inability to detect immunoreactive folate
receptors on Western blots ofmembrane proteins probed with anti-
serum to human folate receptor (unpublished data), it appears
unlikely that high-affinity membrane folate receptors (Antony,
1992) play any significant role in the uptake of F-MTX in the
K562 sublines.] Under these conditions, partial probe displace-
ment from dihydrofolate reductase was seen during MTX co-incu-
bation but not with ZD1694; the former probably reflects partial
probe displacement from dihydrofolate reductase by MTX, as
described previously (Assaraf and Schimke, 1987). Notably,
displacement ofF-MTX cell labelling by MTX could not be iden-
tified in the RFC-transfectants under the same conditions (data not
shown). However, this may simply reflect the greater labelling of
these cells compared with the wild-type cells, as noted above.
Therefore, our report is the first demonstration of a RFC-medi-
ated component for F-MTX cellular uptake in tumour cells. F-
MTX binding to RFC was previously documented in L1210 cells,
but cellular F-MTX uptake, monitored by fluorimetry, was very
slow and largely independent of the RFC (Henderson et al, 1980;
Fan et al, 1991). Although no specific interaction between F-MTX
and the RFC could be documented in Chinese hamster ovary cells
(Assaraf et al, 1989), this may be due to the low sensitivity of the
flow cytometry method used (see above). This observation may
also reflect differences in anti-folate affinities between human and
hamster RFC proteins (Wong et al, 1995). Of course, as noted
above, in all the K562 sublines, F-MTX uptake during prolonged
exposures was also independent ofRFC.
Qualitatively identical results were obtained for F-MTX uptake
into leukaemic blasts from children with ALL. Therefore, for two
specimens previously reported with intact RFC transport, F-MTX
accumulated tohigh levels and was nearly completely abolished by
co-incubation with ZD1694. The labelling intensity in these
samples was more intense than either the wild type or transfected
K562 cells; this probably reflects the significantly reduced cyto-
plasmic content of leukaemic blasts. It was of particular interest
that an additional ALL specimen (sample 12), with impaired MTX
transport by flow cytometry (Matherly et al, 1995), similarly
exhibited impaired F-MTX uptake by confocal microscopy.
Although only 14% of the blasts were previously reported with
defective MTX transport, when assayed with F-MTX and confocal
microscopy, F-MTX uptake was completely suppressed in over
90% of the cells. This seeming discrepancy probably reflects
differences in sensitivity between our earlier indirect flow cytom-
etry assay of RFC transport in ALL specimens (Matherly et al,
1995) and direct visualization oftransport by confocal microscopy.
High concentrations ofdisplacing MTX may preclude detection of
low levels of MTX transport impairment by flow cytometry and
low levels ofdihydrofolate reductase interfere with the detection of
incomplete F-MTX displacement in transport-defective cells. Our
results suggest the potential ofconfocal analysis as a tool for visu-
alizing cellularevents involved in anti-folate uptake and accumula-
tion, including clinical resistance. It will be essential to apply these
methods to a large patient population to establish their general use.
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